Analysis of the prevalence of HIV-1 primary resistance to antiretroviral medicinal agents in Novosibirsk region


DOI: https://dx.doi.org/10.18565/therapy.2022.3.35-41

Kapustin D.V., Krasnova E.I., Khalikov M.R., Pozdnyakova L.L., Khokhlova N.I., Maksimenko L.V., Ekushov V.E., Totmenin A.V., Gashnikova N.M.

1) Novosibirsk State Medical University of the Ministry of Healthcare of Russia; 2) City Infectious Diseases Clinical Hospital No. 1, Novosibirsk; 3) State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor, Koltsovo industrial community, Novosibirsk region
Abstract. Timely detection of HIV variations resistant to antiretroviral medicines (ARM) and correction of the therapeutic direction can prevent the formation of mutations.
The aim of the research is to study the prevalence of primary HIV-1 resistance to ARM in patients with HIV infection in Novosibirsk region in 2021.
Material and methods. We examined 119 patients with newly diagnosed HIV infection aged 22 to 66 years old, who were observed in city clinical hospital No.1 in Novosibirsk in 2021. The nucleotide sequence of HIV-1 genome fragments encoding the protease and reverse transcriptase of the virus was studied, the HIV-1 genotype was determined, and the analysis for the presence of mutations associated with the development of virus resistance to ARM was made.
Results. Among the 119 examined patients with HIV infection, males predominated – 68,1%. Among the ways of HIV infection transmission heterosexual transmission dominated – 61,3%. HIV-1 genotyping revealed 6 HIV genetic variants in 110 patients: subtype A6 (12,7%), subtype B (1,8%), CRF63_02A6 (80,9%), CRF01_AE (1,8%), CRF02_AGFSU (0,9%) and two variants of unique recombinant HIV (URF) formed with the participation of subtype A6 and CRF63_02A6 (0,9% each). According to the main list of mutations subject to surveillance for primary HIV-1 resistance, 16 resistant variants of HIV-1 were found – in 13,4% of the study group of patients. Based on the totality of all identified mutations (including those subject to surveillance), primary resistant variants of HIV-1 were detected in 19,3% of cases (n=23 from 119). More often than others, isolated mutations to drugs from the NNRTI group were registered – in 61,0% (n=14 from 23); isolated mutations to NRTIs were fixed in 21,8% (n=5 of 23), combination of mutations to NRTIs + NNRTIs in 12,9% (n=3 of 23), mutations to PIs + NNRTIs in 4,3% of patients (n=1 from 23). In patients with HIV resistance mutations (n=23), K103N was most common – alone (30,6%) and in combination with P225H or K70T (4,3% each). Most often, a high level of resistance was detected to ARPs of the NNRTI group – efavirenz (7,5%) and nevirapine (8,4%). The average level of resistance in isolated cases was registered to etravirine, rilpivirine and efavirenz (0,8% each).
Conclusion. Among the naive HIV-infected, the prevalence of primary HIV-1 resistance to ART corresponds to the average level for the territories of Russia – 13,4%. Among HIV resistance mutations (n=23), K103N was the most common one (30,6%) and also in combination with P225H and K70T (4,3% each).
Keywords: antiretroviral medicinal agents, AIDS, HIV infection, resistance, mutations
Read entire article

Literature


  1. World Health Organization. HIV/AIDS. URL: https://www.who.int/news-room/fact-sheets/detail/hiv-aids (date of access – 11.03.2022).

  2. Parikh U.M., McCormick K., van Zyl G., Mellors J.W. Future technologies for monitoring HIV drug resistance and cure. Curr Opin HIV AIDS. 2017;12(2): 182–89. https://dx.doi.org/10.1097/COH.0000000000000344.

  3. Alteri C., Svicher V., Gori C. et al. Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs. BMC Infect Dis. 2009; 9: 111. https://dx.doi.org/10.1186/1471-2334-9-111

  4. World Health Organization, United States Centers for Disease Control and Prevention, The Global Fund to Fight AIDS, Tuberculosis and Malaria. HIV drug resistance report 2017. URL: https://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en (date of access – 11.03.2022).

  5. Российская база данных устойчивости ВИЧ к антиретровирусным препаратам. Доступ: https://www.hivresist.ru (дата обращения – 11.03.2022). [Russian database of HIV resistance to antiretroviral drugs. URL: https://www.hivresist.ru (date of access – 11.03.2022) (In Russ.)].

  6. Fanales-Belasio E., Raimondo M., Suligoi B., Butto S. HIV virology and pathogenetic mechanisms of infection: A brief overview. Ann Ist Super Sanita. 2010; 46(1): 5–14. https://dx.doi.org/10.4415/ANN_10_01_02.

  7. Зайцева Н.Н., Парфенова О.В., Пекшева О.Ю. Анализ распространенности первичной резистентности ВИЧ к антиретровирусным препаратам в Приволжском федеральном округе. Медицинский альманах. 2016; 3: 93–95. [Zaitseva N.N., Parfenova O.V., Peksheva O.Yu. Analysis of spread of initial resistance of HIV to antiretroviral medicines in Privolzhsky Federal District. Meditsinskiy al’manakh = Medical Almanac. 2016; 3: 93–95 (In Russ.)].

  8. Бобкова М.Р. Лекарственная устойчивость ВИЧ. М.: Человек. 2014; 288 с. [Bobkova M.R. HIV drug resistance. Moscow: Chelovek = Human. 2014; 288 pp. (In Russ.)]. ISBN: 978-5-906131-42-3.

  9. Hall T.A. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999; 41: 95–98.

  10. Tamura K., Stecher G., Peterson D. et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12): 2725–29. https://dx.doi.org/10.1093/molbev/mst197.

  11. Tang M.W., Liu T.F., Shafer R.W. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012; 55(2): 98–101. https://dx.doi.org/10.1159/000331998.

  12. Bennett D.E., Camacho R.J., Otelea D. et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009; 4(3): e4724. https://dx.doi.org/10.1371/journal.pone.0004724.

  13. Kirichenko A., Kireev D., Lopatukhin A. et al. Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries. PLoS One. 2022; 17(1): e0257731. https://dx.doi.org/10.1371/journal.pone.0257731. pone.0257731

  14. Gashnikova N.M., Zyryanova D.P., Astakhova E.M. et al. Predominance of CRF63 02A1 and multiple patterns of unique recombinant forms of CRF63 A1 among individuals with newly diagnosed HIV-1 infection in Kemerovo Oblast, Russia. Arch Virol. 2017; 162(2): 379–90. https://dx.doi.org/10.1007/s00705-016-3120-4.

  15. Maksimenko L.V., Totmenin A.V., Gashnikova M.P. et al. Genetic diversity of HIV-1 in Krasnoyarsk Krai: Area with high levels of HIV-1 recombination in Russia. Biomed Res Int. 2020; 2020: 9057541. https://dx.doi.org/10.1155/2020/9057541.


About the Autors

Dmitry V. Kapustin, PhD in Medicine, assistant at the Department of infectious diseases, Novosibirsk State Medical University of the Ministry of Healthcare of Russia. Address: 630099, Novosibirsk, 40/4 Sem`i Shamrinykh Str.
E-mail: dmitrij_kapustin_1991@inbox.ru. ORCID: https://orcid.org/ 0000-0002-7060-4710
Elena I. Krasnova, Dr. med. habil, professor, head of the Department of infectious diseases, Novosibirsk State Medical University of the Ministry of Healthcare of Russia. Address: 630099, Novosibirsk, 40/4 Sem`i Shamrinykh Str.
E-mail: krasnova-inf@rambler.ru. ORCID: https://orcid.org/0000-0003-3168-9309
Maxim R. Khalikov, research assistant at the Department of retroviruses, State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor. Address: 630559, Koltsovo industrial community, Novosibirsk region.
E-mail: halikov_mr@vector.nsc.ru
Larisa L. Pozdnyakova, PhD in Medicine, chief physician of City Infectious Diseases Clinical Hospital No. 1. Address: 630099, Novosibirsk, 40/5 Sem`i Shamrinykh Str. E-mail: gikb1@yandex.ru
Natalya I. Khokhlova, PhD in Medicine, associate professor, associate professor of the Department of infectious diseases, Novosibirsk State Medical University of the Ministry of Healthcare of Russia Address: 630099, Novosibirsk, 40/4 Sem`i Shamrinykh Str. E-mail: talitas@bk.ru
Lada V. Maksimenko, junior researcher at the Department of retroviruses, State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor. Address: 630559, Koltsovo industrial community, Novosibirsk region.
E-mail: maksimenko_lv@vector.nsc.ru. ORCID: https://orcid.org/0000-0002-4273-1704.
Vasily E. Ekushov, research assistant at the Department of retroviruses, State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor. Address: 630559, Koltsovo industrial community, Novosibirsk region.
E-mail: ekushov_ve@vector.nsc.ru. ORCID: https://orcid.org/0000-0002-0465-1260
Alexey V. Totmenin, PhD in Biology, senior researcher at the Department of retroviruses, State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor. Address: 630559, Koltsovo industrial community, Novosibirsk region. E-mail: totmenin@vector.nsc.ru. ORCID: https://orcid.org/0000-0002-7418-4872
Наталья Матвеевна Гашникова, PhD in Biology, head of the Department of retroviruses, State Scientific Center for Virology and Biotechnology Vector of Rospotrebnadzor. Address: 630559, Koltsovo industrial community, Novosibirsk region. Адрес: 630559, р.п. Кольцово, Новосибирская область. E-mail: nmgashnikova@gmail.com.
ORCID: https://orcid.org/0000-0002-0891-0880


Similar Articles

Back to Content

Бионика Медиа